Table 1.

CDK12-related samples from ovarian cancer cohorts

Tumor IDsWES/RNA-seqHRDaPloidybBreakpoints/iGainscCDK12 TD-plusCDK12 mutations
TCGA-09-1673+/+No4641/70Yesp.S343fs
TCGA-13-0791−/+No4626/64Yesp.L122×d
TCGA-20-0987+/+No2491/77Yesp.E928Gfsd
TCGA-20-1684+/+No4553/94Yesp.S785fs
TCGA-13-0891−/+No4309/48Yesp.Q1013_L1015del
TCGA-24-1842+/+No4505/68Yesp.R983_E984delQ
TCGA-25-1322+/+No2334/35Yesp.Y901Cd
TCGA-24-1466+/+No4741/76Yesp.L996Fd
TCGA-31-1953+/+No4467/38Yesp.W719×d
TCGA-13-1495+/+No4409/33Yesp.Q602×d
TCGA-61-1918−/+No4498/61Yesp.S62fs
TCGA-24-1920−/−No4846/77YesNA
TCGA-24-2023−/+No4442/43Yesp.S863L
TCGA-42-2588+/−No2396/41YesNot found
TCGA-24-1551+/+No2612/85Yesc.2964-1G>C
TCGA-61-2000+/+Yes2521/67Yesp.A88fs
TCGA-13-1511+/+Yes2367/52Yesp.P58fs
TCGA-29-1711+/+meBRCA12166/15Nop.P653L
TCGA-25-2392+/+BRCA14212/7Nop.R882Le
TCGA-59-2351+/+BRCA2494/3Nop.K975Ef
TCGA-29-1696+/+Yes266/5Nop.A1174G
TCGA-23-1027+/+BRCA1273/2Nop.A943S
TCGA-24-1428+/+meBRCA14160/5Nop.A1414T (rs201512860)
TCGA-61-1900+/+Yes2118/6Nop.I1131V (rs61747430)
TCGA-09-1665−/+meBRCA14301/17Nop.I619V (rs144501352)
TCGA-09-1667−/+No4200/8NoPromoter methylation
TCGA-30-1866−/+No4168/6NoPromoter methylation
MP2−/−Yes2394/46Yesp.H111Qfs
MP3−/−No4900/92Yesp.E72Gfs
MP4−/−Yes4717/77Yesp.K46Sfs
T_52−/−No2347/30Yesp.V919F
PD3722a−/−NANANAYesp.R271X
  • aBRCA1, BRCA1 deleterious mutation; BRCA2, BRCA2 deleterious mutation; meBRCA1, BRCA1 promoter methylation; yes, genomic HRD identified by the LST signature; no, no evidence of genomic HRD.

  • bPloidy detected from the SNP arrays (20).

  • cThe total number of breakpoints and interstitial gains of 2 to 7 Mb (iGains) are shown.

  • dPathogenic.

  • eCDK12/CCNK complex not impaired.

  • fCTD phosphorylation not impaired.

  • d,e,fTested in ref. 8.